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Abstract 
With resources always scarce, limited resources have to be targeted
at those interventions, prevention and cure, that give the greatest pop-
ulation health gain at least cost. Mere identification of what works in
prevention is inadequate unless this evidence is supplemented with
economic analysis that identifies what is cost effective. Public health
without the use of economics is incomplete.
Introduction
All countries have to make difficult choices about how to allocate
scarce resources amongst competing uses. Everywhere there is contin-
uous debate about the size of the public sector and the need to balance
this against the funding of a vigorous private sector. Within the public
sector difficult choices have to be made between and within essential
services such education, defence and health care. The health care sec-
tor consumes ten per cent of national income in many countries. It is
characterised by increasing demand due to the ageing of populations
and technological change, rising expenditures and a debate about the
relative roles of curative medicine and investments in public health.
An appealing analogy is that investment upstream on prevention
would save subsequent expenditure downstream on care and cure. But
is prevention better than cure, and if so which interventions offer the
greatest benefit to patients at least cost? Given the universal scarcity
of resources, economic recession and austerity, answers to this crucial
question remain elusive. How can knowledge about the relative pro-
ductivity of investing in curative and preventive care be improved?
The distinction between a discipline and a subject
A discipline is a way of analysing the world which creates hypothe-
ses that are subject to empirical testing. It is a mode of thinking that
facilitates the use of particular concepts and relationships that can be
used to ask questions and collect data. Over time such work creates a
body of knowledge that can be taught and augmented.1 Examples of
social science disciplines particularly relevant to the production of
health and health care are psychology, sociology and economics.
A subject is an area of discourse where disciplines are deployed to
increase understanding. History, medicine and public health are three
areas which can be called subjects. These topics can be explored using
social science disciplines. For instance Fogel and Engerman2 postulat-
ed that slavery in the USA was economically efficient (if morally repug-
nant). They used economic techniques and data to explore historical
data and reach their conclusions.
Social medicine, community medicine and public health are three
titles of discourse on the subject of health production. Many decades
ago it was defined by Holland3 as a subject that covers the organisation
and evaluation of health care systems and the medical aspects of the
administration of health care service. Nowadays the subject public
health covers not only the production and distribution of health care
but also the production and distribution of health.
The subject of public health involves use of a broad range of activi-
ties, only some of which are disciplines e.g. epidemiology, statistics,
sociology, social policy, public administration, management, psycholo-
gy, operations research and planning. Of theses some are disciplines
and some are not e.g. epidemiology which involves the analysis of the
causes and distribution of disease in populations rather than individ-
uals is a discipline like the social sciences. However social policy and
management are topics like public health. The vigour and success of a
subject such as public health depends on the complementary use of a
range of disciplines. The choice of the particular discipline depends on
the question to be addressed. Public health exhibits a peculiar defi-
ciency: the relative neglect of the use of economics. The poor exploita-
tion of the discipline of economics by public health practitioners is
epitomised by the Marmot report.4 This report was commissioned by
the Labour Government and focused the identification of inequalities
in health in the United Kingdom and how these long established vari-
ations could be reduced. The report concluded that investment in
remedial policies was required in six areas: give every child the best
start in life; enable all children, young people and adults to maximise
their capabilities and have control over their lives, create fair employ-
ment and good work for all; ensure a healthy standard of living for all;
create and develop healthy and sustainable places and communities;
strengthen the role and impact of ill health preventions.
This list whilst appealing at a general level is extraordinarily vague.
It begs answers to two crucial questions that can only be answered by
economic evaluation of competing investments in public health. Firstly
how are these policy objectives ranked? Secondly what trade-offs are
there within and between each group? Answering these questions
requires collaborative use of techniques of economic evaluation.
Failure to address these issues leaves decision makers ill informed
about how to prioritise investments in the production of health. Such
ignorance is not bliss as it is likely to waste scarce economic resources
and frustrate improvements in public health and reductions in health
inequalities. 
Significance for public health
Public health is an important subject which requires the application of the
discipline of health economics to facilitatte the identification of cost effec-
tive  interventions to improve public health. Without this targeting public
health investment is faith based rather than evidence based.
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The myopia of public healthThe poverty of the effectiveness evidence base
Public health is a subject area of great policy importance but its devel-
opment has been myopic. Returning to the issue of health inequalities,
where the United Kingdom and the United States have despite their rel-
ative affluence some of greatest health inequalities in the developed
world, there continues to be political and social concern but a failure to
develop evidence based remedial policies. In the UK there have been a
series of reports over decades: the Black report,5 the Acheson report,6 and
more recently the Marmot report.4 These reports have offered great detail
about differences in mortality and morbidity of rich and poor groups,
exploiting cross section and cohort data Each of these UK  reports has
described in great detail the differences in life expectation, mortality and
morbidity of rich and poor social groups.  Each report has attracted high
levels of public interest and political agreement that such inequalities
should be reduced. However a characteristic of this very pertinent work
has been an absence of detail about which types of investment would be
most efficient in reducing health inequalities.
For instance, with a child born today in deprived Glasgow in Scotland
having a life expectation at least a decade less than a child born in
affluent Kensington and Chelsea in London, the policy question is how
can than inequality be reduced best at least cost? The answers given by
the public health-social epidemiology literature are poor. For instance
is it best to target resources at young children and develop in their first
three years of life their cognitive and non cognitive skills, thereby
enhancing their life time earnings potential and capacity to invest in
health activities? If the answer to this question is yes, which policy
interventions are most cost effective? Investing in health production in
this way implies relative neglect of older children and adults, leaving
them to their fate and premature death and excess morbidity during
their lifetimes. Where is the evidence that this is an efficient policy?
In both the public health and the economics literature on the reduc-
tion of health inequalities there appears to be a consensus that invest-
ment in interventions in the early years, particularly pre-school, are
likely to be more efficient. Investment later, for instance in teenagers,
is unlikely to be good value for money as their cognitive and non cog-
nitive skills may be difficult to improve compared to those in early life.7
The public health-social epidemiology approach to inequality if it
neglects economics will continue to myopic, providing a diagnosis but
little insight into the efficient treatment of the problem. How can eco-
nomics and public health be married or better integrated to produce
more efficient and comprehensive public policy.   
An essential first step is the identification of interventions that are
demonstrably effective. This task is not easy as the literature is often
poor in terms of trial design and reporting. For instance Katikireddi and
colleagues8 have analysed a recent English policy document which
espouses investment in those interventions that are effective. They
show how current politicians offer the rhetoric of funding only those
investments that are demonstrably effective. However despite their
good intent, Katikireddi and his colleagues show that the quantity and
quality of evidence of effectiveness is limited and some government
policies lack an evidence base of effectiveness They appraise evidence
for a range of policies: early years, physical activity, food, community
interventions, and inequalities and show the limits of the evidence
base.
The result of poor evaluation of effectiveness of public health inter-
ventions is that policies tend to be based on faith rather than evidence.
This is epitomised by advocacy of smoke free environments. Does the
banning of smoking in public places such as restaurants and bars reduce
tobacco consumption? A study comparing smoke free legislation in
Scotland with England prior to its banning smoking in public places has
shown that it had no effect on tobacco consumption in Scotland.9 The pol-
icy may have reduced passive smoking mortality and morbidity, for which
there is no comparable data, and improved environmental cleanliness
but its effect on tobacco consumption appears to be zero. This analysis
demonstrates nicely to need to evaluate policies carefully.The poverty of the cost effectiveness evidence base
Evidence of effectiveness is a necessary but not a sufficient criteri-
on for investment in the production of health in the curative or the pub-
lic health sectors. What is effective may not be cost effective but what
is cost effective is always effective.10
Assume that intervention A produces 50 quality adjusted life years
(QALYs or years of good quality life) and intervention B produces 250
QALYs. The myopic medical paradigm, and the patient or beneficiary
from such investment would choose intervention B as it produces the
best outcome i.e. 200 more QALYs than investing in intervention A.
However, this conclusion is premature as it ignores the cost of the
alternatives. All investment decisions involve an opportunity cost i.e. a
decision to spend on one option deprives the beneficiaries of another
option of benefits. All investment choices involve foregoing benefits
from programmes not financed.
If we assume that intervention A costs £500 and intervention B costs
£5000, this means that A produces each QALY at the cost of £10 whilst
intervention B produces each QALY at a cost of £20. If the programme
budget is £100000, intervention A which is least effective produces
10000 QALYs whilst intervention B (the more effective) produces only
5000 QALYs.
Thus when investing in health care, curative and public health, evi-
dence is needed of effectiveness and cost effectiveness of competing
interventions. Katikireddi and colleagues8 show how the effectiveness
evidence base is generally quite limited. They could have usefully
developed their argument and noted more thoroughly that the cost
effectiveness evidence base is even poorer.Why is the evidence base poor?
Why is the quality of effectiveness and cost effectiveness research in
public health so poor? It seems that the lessons disseminated by the
Cochrane Collaboration (www.cochrane.org ) have failed to affect prac-
tice in public health. The quality of trials and systematic reviews are
inadequate to inform public policy making. The problem, as Chalmers
has emphasised in his criticism of research in curative medicine, is
not lack of resources but the poor quality of research work.11
However, public health research is not easy to design and imple-
ment. The literature exhibits a tendency to select multiple end points
for appraisal when single end points might be preferred. The benefits
of public health interventions may accrue over decades. How long
should trials continue e.g. when measuring tobacco quit rates success
within the year may be cancelled out later by smoking resumption?
Costing interventions for essential cost effectiveness studies is
essential but difficult. However health care systems generally have
poor unit cost data as audit and performance management systems
tend to be focused on macro expenditure control i.e. staying in budget.
What costs should be included in an evaluation? Should it focus on the
costs to the local health service? Or should health service costs and
costs to the patient and their carers also be included? The English
National Institute for Health and Clinical Excellence (NICE) is required
to carry out technology and public health appraisals focused only on the
costs to the NHS of the competing interventions and ignores broader
social cost issues.
Another complex aspect of economic evaluation which is particular-
ly acute in public health is the discounting costs and benefits. The fun-
damental issue is that we all tend to exhibit time preference. If offered
£100 now or £100 in a year’s time, most would opt for £100 now i.e. they
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prefer benefits now to benefits in the future. If offered the choice of
paying a debt now or paying it off in the future, most would prefer to
delay payment and pay in the future. When carrying out economic eval-
uation what choice of discount rates` should be used for costs and ben-
efits? Should the rates be the same for costs and benefits? Currently
the English NICE uses different discount rates for cost and benefits: six
per cent for costs and one and a half per cent for benefits. Further dis-
cussion of these contentious issues can be found in textbooks.12,13
The combined effects of poor evaluation of the effectiveness and the
reluctance of public health practitioners to incorporate economic eval-
uation into their work has created a paucity of evidence to inform
investment in public health. As ever, and in medicine, the volume of lit-
erature is substantial and growing but sadly its quality is poor .This
problem is epitomised by the work of NICE which although charged
with the task of evaluating public health policies is finding it difficult
to make progress due to the poor quality of effectiveness and econom-
ic data being reported in the literature.
Public health and economics: the need for marriage 
The topic of public health is not making sufficient impact on
resource allocation in all health care systems. The important issues it
raises, as epitomised by the analysis of health inequalities, tend to cre-
ate considerable public interest but little impact on the use of
resources. This is a product of both the failure of the public health
industry to conduct and report well designed trails of the effectiveness
of the policies they espouse and their failure to include cost compo-
nents in their studies. The absence of cost data and the absence of eco-
nomic evaluation make prioritisation of competing investments impos-
sible. In the absence of economic data resources are` allocated on the
basis of rhetoric and political opportunism. This ensures waste with
patients and populations being deprived of health benefits they value.
Such inefficiency is unethical. Its mitigation requires that the prac-
titioners of the arts and science of public health embraces the tech-
niques of economic evaluation urgently and comprehensively. Such a
marriage is surely made in heaven and would benefit all societies!
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